TB Archives – Page 12 of 48 – Treatment Action Group

TAG Celebrates TB Advocacy Award for Senior Policy Officer Elizabeth Lovinger

June 25, 2021
Dorrit Walsh

TAG joins the U.S. National TB Controllers Association (NTCA) in celebrating our dedicated and brilliant Senior Government Relations and Policy Officer, Elizabeth (Lizzy) Lovinger, who today received the 2021 Charles DeGraw TB Advocacy Award.

Research in Action Awards 2021

June 16, 2021
Dorrit Walsh

On November 16, we honored CDC Director Rochelle Walensky, MD, MPH; Ivy Kwan Arce, activist, mother, and artist living with HIV; and Erica Lessem, MPH, former TAG Deputy Executive Director.

2020 Annual Report

June 4, 2021
Dorrit Walsh

As the HIV epidemic changes over time, and new pandemics continue to emerge, TAG continues to evolve while remaining true to our activist roots. We partner with the most affected communities in the U.S. and around the world.

TAG Urges Governor to Sign New York State Bill Expanding Adult Vaccines Available in Pharmacies

June 3, 2021
Dorrit Walsh

The bill, S4807A (Stavisky) / A6476A (Hyndman), improves preventive viral hepatitis vaccine access, and is particularly important for people who use drugs and unhoused New Yorkers.

Community Engagement on TB through Storytelling

May 24, 2021
Dorrit Walsh

Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. These storyboards follow three individuals journeys through diagnosis, treatment and care, and the barriers they face.

Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs

May 10, 2021
Dorrit Walsh

The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.

The TB Research Engine That Could: Sustaining the Success of TBTC Research in Turbulent Times

May 10, 2021
Dorrit Walsh

This publication explores the critical role the Tuberculosis Trials Consortium holds in increasing the store of knowledge about TB cures and other tools, demonstrates the implications that a lack of funding will have across the TB pipeline, and offers recommendations to ensure the gains made in TB research are not lost.

TAG Welcomes U.S. Government Support of Intellectual Property Flexibilities to Enable COVID-19 Vaccine Access

May 6, 2021
Dorrit Walsh

Treatment Action Group (TAG) applauds the U.S. government’s decision to support the India-South Africa proposed waiver of certain intellectual property rights to enable equitable access to life-saving interventions for COVID-19.

Landmark TB Trials Results Published in New England Journal of Medicine

May 6, 2021
Dorrit Walsh

Today the New England Journal of Medicine published results of a landmark phase III clinical trial that found a 4-month regimen containing rifapentine and moxifloxacin performed as well as the six-month standard regimen in curing drug-susceptible pulmonary TB.

TAG Comments on NIST’s Proposed Rulemaking Changes

April 4, 2021
Dorrit Walsh

TAG submitted comments in response to the National Institute of Standards and Technology's (NIST) proposed change to rulemaking, strongly opposing amendments to remove crucial public health safeguards from the Bayh-Dole Act. March-in rights and other provisions to hold manufacturers accountable when federally funded inventions are exorbitantly priced and are critically important to public health and the right to science.